Our Terms of Service and Privacy Policy have changed.
By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.
By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.
| 0.848 Delayed Data As of May 26 |  -0.002 / -0.24%Today’s Change | 0.71 Today|||52-Week Range 1.42 | -7.83% Year-to-Date |
| BioLineRx Makes Regulatory Submission for Trial of BL-8040 May 23 / Zacks.com - Paid Partner Content |
| Previous close | 0.85 |
| Today’s open | 0.85 |
| Day’s range | 0.83 - 0.86 |
| Volume | 333,434 |
| Average volume (3 months) | 545,449 |
| Market cap | $81.3M |
| Dividend yield | -- |
| Earnings growth (last year) | -0.36% |
| Earnings growth (this year) | -- |
| Earnings growth (next 5 years) | -- |
| Revenue growth (last year) | -- |
| P/E ratio | -- |
| Price/Sales | -- |
| Price/Book | 1.39 |
| Today’s change | Today’s % change | |
|---|---|---|
| NOVNNovan Inc | +0.09 | +1.86% |
| NVETNexvet Biopharma plc | +0.01 | +0.11% |
| LIFEaTyr Pharma Inc | -0.10 | -2.94% |
| NNVCNanoViricides Inc | -0.01 | -0.72% |
| Next reporting date | August 10, 2017 |
| EPS forecast (this quarter) | -$0.07 |
| Annual revenue (last year) | $0.00 |
| Annual profit (last year) | -$15.9M |
| Net profit margin | -- |
Sector Health Technology |
Industry Pharmaceuticals: Other |
Chief Executive Officer & Head-Investor Relations Philip Adam Serlin |
Chief Financial Officer Mali Zeevi |
Corporate headquarters Modi'in, Tel Aviv |
